Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 851 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Turning the Life Sciences Vision into reality July 9, 2021 Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient... May 31, 2024 The 10 Things That Helped Me Cope With My 2 Cancer... February 6, 2024 COVID-19 vaccine and cancer – latest updates November 20, 2020 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Durvalumab to Patients with... Changes in Metabolism Help Melanomas Spread Her Mother Died of Breast Cancer When She Was Five. 16... Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed...
